Focus on niche markets, efficiency turn Biogen around

12/6/2012 | Forbes

George Scangos has turned around Biogen Idec by getting out of highly competitive markets, such as oncology, and focusing on areas where Big Pharma sometimes fears to tread, such as neuroscience and hemophilia. Sales chief Tony Kingsley's strategy of focusing on top-selling drug Avonex instead of the troubled multiple sclerosis drug Tysabri kept revenue flowing and allowed the company to develop BG-12, an MS drug in pill form instead of an injection. Now Scangos is cutting the bureaucracy usually inherent in drug development to refill the company's pipeline.

View Full Article in:

Forbes

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Medical Device Reimbursement Specialist - Regional
Alcon
Fort Worth , TX
Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group
Genentech
94080, CA
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX